Nama's AI scorecard currently rates ICU Medical Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ICUI's P/E ratio?

ICU Medical trades at a trailing price-to-earnings ratio of 19.8.

When does ICUI report earnings?

ICU Medical's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $2.23.

What is the ICUI price target?

The median analyst price target from 8 analysts is $192.50, with a range of $178.00 – $210.00.

Is ICUI Shariah compliant?

Nama's AAOIFI-style screen reads ICU Medical as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

ICU Medical (ICUI)

Healthcare · Medical Instruments Supplies · NASDAQ

ICU Medical (ICUI) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $4.30B, a trailing price-to-earnings ratio of 19.8 and a free-cash-flow yield of 1.9%. Over the most recent reported fiscal year, revenue declined 6.3% and free cash flow per share fell 28.7%. Nama's AI scorecard rates it Buy, 6.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.2/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +20.3% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-31.6%

How far the last close sits under the highest price of the past five years.

Market cap	$4.30B
Trailing P/E	19.8
Price / book	2.0
Price / sales	2.0
FCF yield	1.9%
Dividend yield	—
Gross margin	39.1%
Operating margin	6.7%
Net margin	1.4%
Revenue growth (YoY)	-6.3%
Revenue growth (3-yr annual)	-0.7%
EPS growth (YoY)	+24.8%
FCF/share growth (YoY)	-28.7%
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

ICUI earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate $2.23). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$2.44	$2.15	+13.5%	—
Q2 2026	Aug 6, 2026	$2.37	$1.91	+24.1%	$551.68M
Q1 2026	May 7, 2026	$1.97	$1.75	+12.6%	$530.23M
Q4 2025	Feb 19, 2026	$1.91	$1.69	+13.0%	$540.70M

ICUI analyst price target

Median target $192.50 from 8 analysts, ranging $178.00 – $210.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live ICUI data on Nama Insights →

Recent Congressional trades

ICU Medical trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Jun 6, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Nov 6, 2024
Thomas R Tillis	Senate	Sell	$1,001 - $15,000	—

ICUI FAQ

Is ICUI a buy?: Nama's AI scorecard currently rates ICU Medical Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ICUI's P/E ratio?: ICU Medical trades at a trailing price-to-earnings ratio of 19.8.
When does ICUI report earnings?: ICU Medical's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $2.23.
What is the ICUI price target?: The median analyst price target from 8 analysts is $192.50, with a range of $178.00 – $210.00.
Is ICUI Shariah compliant?: Nama's AAOIFI-style screen reads ICU Medical as Not Shariah Compliant. At least one of the three ratios or the industry test failed.